Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chinyu Su

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Journal of Crohn'S & Colitis|September 20, 2022
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical ProgrammeWilliam J Sandborn, Geert R D'Haens, Bruce E Sands, et al.
Journal of Crohn'S & Colitis|November 27, 2020
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical ProgrammeKevin L Winthrop, Edward V Loftus, Daniel C Baumgart, et al.
Therapeutic Advances in Gastroenterology|March 3, 2025
Potential predictors of efficacy outcomes following tofacitinib dose reduction in patients with ulcerative colitis in stable remission: a post hoc analysis of outcomes from the RIVETING studyJoana Torres, Geert R D'Haens, Miguel Regueiro, et al.
Journal of Crohn'S & Colitis|October 14, 2017
Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance StudiesJulian Panés, Séverine Vermeire, James O Lindsay, et al.
Journal of Crohn'S & Colitis|November 10, 2018
Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance StudiesJulian Panés, Séverine Vermeire, James O Lindsay, et al.
Inflammatory Bowel Diseases|April 5, 2022
Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical ProgramMarla C Dubinsky, Fernando Magro, Flavio Steinwurz, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2018
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative ColitisStephen Hanauer, Remo Panaccione, Silvio Danese, et al.
Alimentary Pharmacology & Therapeutics|December 2, 2021
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatmentWilliam J Sandborn, Nervin Lawendy, Silvio Danese, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 12, 2019
Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative ColitisBruce E Sands, Pam R Taub, Alessandro Armuzzi, et al.
Journal of Crohn'S & Colitis|July 4, 2023
Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical ProgrammeStefan Schreiber, David T Rubin, Siew C Ng, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Journal of Crohn'S & Colitis|September 20, 2022
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical ProgrammeWilliam J Sandborn, Geert R D'Haens, Bruce E Sands, et al.
Journal of Crohn'S & Colitis|November 27, 2020
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical ProgrammeKevin L Winthrop, Edward V Loftus, Daniel C Baumgart, et al.
Therapeutic Advances in Gastroenterology|March 3, 2025
Potential predictors of efficacy outcomes following tofacitinib dose reduction in patients with ulcerative colitis in stable remission: a post hoc analysis of outcomes from the RIVETING studyJoana Torres, Geert R D'Haens, Miguel Regueiro, et al.
Journal of Crohn'S & Colitis|October 14, 2017
Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance StudiesJulian Panés, Séverine Vermeire, James O Lindsay, et al.
Journal of Crohn'S & Colitis|November 10, 2018
Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance StudiesJulian Panés, Séverine Vermeire, James O Lindsay, et al.
Inflammatory Bowel Diseases|April 5, 2022
Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical ProgramMarla C Dubinsky, Fernando Magro, Flavio Steinwurz, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2018
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative ColitisStephen Hanauer, Remo Panaccione, Silvio Danese, et al.
Alimentary Pharmacology & Therapeutics|December 2, 2021
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatmentWilliam J Sandborn, Nervin Lawendy, Silvio Danese, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 12, 2019
Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative ColitisBruce E Sands, Pam R Taub, Alessandro Armuzzi, et al.
Journal of Crohn'S & Colitis|July 4, 2023
Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical ProgrammeStefan Schreiber, David T Rubin, Siew C Ng, et al.
Pageof 7